奥妥珠单抗联合大剂量阿糖胞苷诱导方案在适合移植的初治套细胞淋巴瘤中的分子学缓解:LyMa-101 Ⅱ期试验
LyMa-101 是一项法国 LYSA 组的开放标签单臂Ⅱ期试验,纳入 86 例 18 至 <66 岁适合自体干细胞移植的初治套细胞淋巴瘤患者,给予 4 周期奥妥珠单抗联合 DHAP 诱导。主要终点为诱导结束时骨髓微小残留病(MRD)阴性率,疗效集 73 例中 55 例(75%)达到骨髓 MRD 阴性。方案耐受性良好,最常见 3-4 级不良事件为贫血和中性粒细胞减少,无治疗相关死亡。
要点
- 奥妥珠单抗联合 DHAP 诱导在适合移植的初治套细胞淋巴瘤中骨髓 MRD 阴性率达 75%。
- 最常见 3-4 级不良事件为贫血(3 级 31%,4 级 4%)和中性粒细胞减少(3 级 15%,4 级 38%)。
- 诱导期发生 58 例严重不良事件,无治疗相关死亡。
核心结论
- 奥妥珠单抗联合 DHAP 耐受性良好,在适合移植的套细胞淋巴瘤患者中诱导骨髓 MRD 阴性活性良好。
- 骨髓 MRD 阴性可能预测长期疾病控制。
研究设计与样本
- LyMa-101 为前瞻性、开放标签、单臂Ⅱ期试验,由法国 LYSA 组开展,纳入 28 家医院。
- 纳入 86 例 18 至 <66 岁适合自体干细胞移植的初治套细胞淋巴瘤患者。
- 给予 4 周期奥妥珠单抗联合 DHAP 诱导后移植,继以 3 年奥妥珠单抗维持及基于 MRD 的按需维持。
- 主要终点为诱导结束时骨髓 MRD 阴性率,疗效集为至少接受一剂奥妥珠单抗且 MRD 可评估(骨髓或外周血)的患者。
主要发现
- 疗效集 73 例中 55 例(75%)在诱导结束时达到骨髓 MRD 阴性。
- 疗效集 73 例中 18 例(25%)为 MRD 阳性:12 例骨髓 MRD 阳性、2 例诱导期进展、4 例未行 MRD 评估。
- 最常见 3-4 级治疗中出现的不良事件为贫血(3 级 26/85 例[31%],4 级 3/85 例[4%])和中性粒细胞减少(3 级 13/85 例[15%],4 级 32/85 例[38%])。
- 诱导期发生 58 例严重不良事件,无治疗相关死亡。
关键数值与推荐
- 方案定义骨髓 MRD 阴性率≥70%(意向治疗)为奥妥珠单抗联合 DHAP 有效。
- 奥妥珠单抗 1000 mg/m2 静脉给药:第 1 周期第 1、8、15 天,第 2-4 周期第 1 天。
- 地塞米松 40 mg 静脉给药第 1-4 天;阿糖胞苷 2 g/m2 静脉给药每 12 小时一次第 1 天。
- 顺铂 100 mg/m2 持续输注 24 小时第 1 天,或卡铂 AUC 5,或奥沙利铂 130 mg/m2,每 21 天一次。
- 移植后奥妥珠单抗维持 1000 mg/m2 每 2 个月一次,共 3 年,继以基于 MRD 的按需维持。
临床怎么用
- 对于适合自体干细胞移植的初治套细胞淋巴瘤患者,可考虑奥妥珠单抗联合 DHAP 作为诱导方案。
- 诱导后应评估骨髓 MRD 状态,MRD 阴性可能提示长期疾病控制。
- 治疗期间需重点监测贫血和中性粒细胞减少等血液学不良事件。
局限性
- 本研究为单臂Ⅱ期试验,无随机对照。
- 样本量有限,共纳入 86 例患者。
- 疗效集 73 例中有 4 例未行 MRD 评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obinutuzumab monotherapy has shown promising efficacy in mantle cell lymphoma. We aimed to investigate the activity of obinutuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin), measured by minimal residual disease quantitative (q)PCR status in the bone marrow after four cycles. METHODS: LyMa-101 was a prospective, open-label, single-arm, phase 2 trial. Participants were enrolled from 28 hospitals in France. Newly diagnosed patients with mantle cell lymphoma (aged 18 to <66 years) who were eligible for autologous stem-cell transplantation received four cycles of obinutuzumab plus DHAP (obinutuzumab 1000 mg/m2 intravenously on days 1, 8, and 15 at cycle 1 and day 1 at cycles 2, 3, and 4; dexamethasone 40 mg intravenously on days 1-4, cytarabine 2 g/m2 intravenously every 12 h on day 1, and according to local investigator, cisplatin 100 mg/m2 by continuous infusion over 24 h on day 1 or carboplatin area under the curve 5 or oxaliplatin 130 mg/m2) every 21 days before transplantation, and 3 years of obinutuzumab (1000 mg/m2 every 2 months) maintenance followed by minimal residual disease-based obinutuzumab on-demand maintenance. The primary outcome was minimal residual disease negativity in the bone marrow after four cycles of obinutuzumab plus DHAP at the end of induction, measured in the efficacy set (all minimal residual disease-informative [bone marrow or peripheral blood] patients who received at least one dose of obinutuzumab). Obinutuzumab plus DHAP was considered effective if bone marrow minimal residual disease negativity was 70% or more by intention to treat. The trial is closed to recruitment and registered with ClinicalTrials.gov, NCT02896582. FINDINGS: 86 patients were enrolled between Nov 29, 2016, and May 2, 2018. 81 patients completed induction, 73 underwent autologous stem-cell transplantation, and 69 started maintenance therapy. 55 (75%) of 73 patients in the efficacy set reached minimal residual disease negativity in bone marrow at end of induction. According to the protocol definition, 18 (25%) of 73 patients in the efficacy set were minimal residual disease-positive: 12 patients who were minimal residual disease-positive in the bone marrow, plus two patients who progressed during induction, and four patients who did not have minimal residual disease assessment. The most common grade 3-4 treatment-emergent adverse events were anaemia (grade 3, 26 [31%] of 85 patients; grade 4, three [4%] of 85 patients) and neutropenia (grade 3, 13 [15%] of 85 patients; grade 4, 32 [38%] of 85 patients). 58 serious adverse events occurred during the induction phase. There were no treatment-related deaths. INTERPRETATION: Obinutuzumab plus DHAP is a well tolerated regimen and has good activity for inducing minimal residual disease negativity in the bone marrow of transplant-eligible patients with mantle cell lymphoma. Obinutuzumab plus DHAP has potential activity as induction chemotherapy, with bone marrow minimal residual disease negativity potentially predicting long-term disease control. FUNDING: Roche SAS.
引用
- Le Gouill S, Beldi-Ferchiou A, Alcantara M, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020. PMID: 32971036. doi:10.1016/S2352-3026(20)30291-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。